Array up 11% on asthma drug PhII despite unclear competitive potential
This article was originally published in Scrip
Executive Summary
Array Biopharma rose 11% on 23 July after ARRY-502 hit its primary endpoint in a Phase II asthma study, and seems effective in a biomarker-defined sub-population. Despite investor enthusiasm though, the early indications are that because of generic competition the oral CTh2 antagonist has most commercial potential only in that subgroup, which represents about a quarter of the total asthma population.